Latus Bio raised $97 million to advance its pipeline of AAV gene therapies for the treatment of central nervous system diseases, including Huntington’s disease and CLN2 disease, both rare disorders.
All entries for: Investment
April 23, 2026
VasoRx
Investment
VasoRx raised $31.89 million to advance its RNA therapy platform for the treatment of pulmonary hypertension, a rare cardiovascular disease.
Disease Area: Rare Diseases
April 22, 2026
ReviR Therapeutics
Investment
ReviR Therapeutics received an undisclosed amount of funding to advance its pipeline of disease-modifying RNA-targeting therapies for the treatment of Huntington’s disease and Charcot-Marie-Tooth disease, both rare neurological disorders.
Disease Area: Rare Diseases
April 1, 2026
Kalevala Therapeutics
Investment
Kalevala Therapeutics received an undisclosed amount of funding to advance its platform for repurposing existing drugs into therapies for underserved rare diseases, including Gaucher disease and Sturge-Weber syndrome.
Disease Area: Rare Diseases
March 24, 2026
EpiFrontier Therapeutics
Investment
Pennington NJ
1-50 employees
EpiFrontier Therapeutics received $32 million to advance EPF-001 for the treatment of sickle cell disease, a rare blood disorder.
City: Pennington
State: NJ
Investment Amount (In Millions): $32
March 16, 2026
Modulation Therapeutics
Investment
Morgantown WV
1-50 employees
Modulation Therapeutics received a $2 million investment to advance therapies for metastatic uveal melanoma, a rare cancer.
City: Morgantown
State: WV
Investment Amount (In Millions): $2
March 11, 2026
Vima Therapeutics
Investment
Cambridge MA
1-50 employees
Vima Therapeutics raised $100 million to advance their pipeline of drugs, including a treatment for isolated dystonia.
City: Cambridge
State: MA
Investment Amount (In Millions): $100
March 9, 2026
Spinogenix
Investment
Los Angeles CA
1-50 employees
Spinogenix raised $10.61 million to advance therapies for Fragile X Syndrome, a rare neurodevelopmental disorder.
City: Los Angeles
State: CA
Investment Amount (In Millions): $10.61
March 5, 2026
Atavistik Bio
Investment
Atavistik Bio raised $160 million to advance precision allosteric small molecules for the treatment of rare diseases and precision oncology.
City: Cambridge
State: MA
Investment Amount(In Millions): $160
March 3, 2026
Prolium Bioscience
Investment
New York
1-50 employees
Prolium Bioscience raised $50 million to advance therapies for systemic sclerosis (SSc), or scleroderma, a rare, chronic autoimmune disease characterized by vascular injury, immune system dysregulation, and progressive fibrosis affecting both the skin and vital internal organs, including the lungs, heart, and gastrointestinal tract.
City: New York
State: NY
Investment Amount(In Millions): $50